Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Synchrotope TA2M · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Synchrotope TA2M, 800 micrograms | EXPERIMENTAL | Tyrosinase peptides, 800 micrograms |
| Synchrotope TA2M, 200 micrograms | EXPERIMENTAL | Tyrosinase peptides, 200 micrograms |
| Synchrotope TA2M, 400 micrograms | EXPERIMENTAL | Tyrosinase peptides, 400 micrograms |
| Name | Type | Description |
|---|---|---|
| Synchrotope TA2M | BIOLOGICAL | Cancer Vaccine, Immunotherapy |
INCLUSION CRITERIA - Patient must meet the following during the screening and baseline visits: 1. The patients or their legally acceptable representative must give signed informed consent for participation in the study before any study procedure is performed. 2. Patients must be 18 years of age or ...
Top 20 of 52 competitors
Synchrotope TA2M is being studied for the treatment of melanoma, specifically skin melanoma. It was evaluated in a Phase 1 trial in patients with Stage IV melanoma. It is an investigational therapy and is not an approved treatment.
Synchrotope TA2M is being developed by MannKind Corporation, which trades under the ticker MNKD. The company is the sponsor of the clinical program for this monoclonal antibody in melanoma.
Synchrotope TA2M is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The program enrolled 26 patients in total.
Synchrotope TA2M was studied in the completed Phase 1 trial NCT00023647, titled Vaccine Therapy in Treating Patients With Stage IV Melanoma. The trial enrolled 26 patients in the United States and included adults 18 years and older.
Synchrotope TA2M is not approved. It is an investigational monoclonal antibody that has completed a single Phase 1 trial in Stage IV melanoma, and no active trials are ongoing.